Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Weekly Maintenance Bortezomib and Rituximab in Mantle Cell Lymphoma Post Autologous Hematopoietic Cell Transplantation

NCT01267812 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT01267812
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01267812 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Weekly Maintenance Bortezomib and Rituximab in Mantle Cell Lymphoma Post Autologous Hematopoietic Cell Transplantation
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Completed
Start date
October 3, 2011
Completion date
November 2, 2020
Enrollment
23 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

contiguous stage ii mantle cell lymphoma, noncontiguous stage ii mantle cell lymphoma, recurrent mantle cell lymphoma, stage i mantle cell lymphoma, stage iii mantle cell lymphoma, stage iv mantle cell lymphoma